依达拉奉右莰醇治疗高龄血管性痴呆患者的临床效果分析

Clinical Efficacy Analysis of Edaravone and Dexborneol in the Treatment of Elderly Patients with Vascular Dementia

目的:分析依达拉奉右莰醇治疗对高龄血管性痴呆患者的有效性及对其认知功能的影响。方法:选取昌邑市人民医院2023年11月—2024年3月就诊的90例高龄血管性痴呆患者作为本研究对象,利用随机数字表法将其分为对照组(n=45)和观察组(n=45)。对照组采用常规药物治疗,观察组则在对照组基础上给予依达拉奉右坎醇静脉滴注。两组均治疗4周。比较两组治疗前后的认知功能[简易智能精神状态评价(MMSE)量表、蒙特利尔认知评估(MoCA)量表评分]、临床痴呆程度[临床痴呆程度量表(CDR)评分]、日常生活能力[改良Barthel指数(MBI)]和超氧化物歧化酶(SOD)水平、丙二醛(MDA)、干扰素(IFN-γ)、同型半胱氨酸(Hcy)水平,评估两组临床疗效。结果:与治疗前相比,两组治疗后的CDR评分、MDA水平、Hcy水平、IFN-γ水平均降低,且观察组均低于对照组,差异均有统计学意义(P<0.05);与治疗前相比较,两组治疗后的MMSE评分、MoCA评分、MBI、SOD水平均提高,且观察组均高于对照组,差异均有统计学意义(P<0.05);观察组临床总有效率为93.33%,高于对照组的77.78%,差异有统计学意义(P<0.05)。结论:依达拉奉右莰醇治疗能有效改善高龄血管性痴呆患者的认知功能与行为能力,降低氧化应激,提升治疗总有效率。

Objective:To analyze the efficacy of Edaravone and Dexborneol in elderly patients with vascular dementia and its effect on cognitive function.Method:Ninety elderly patients with vascular dementia treated in Changyi People's Hospital from November 2023 to March 2024 were selected as the subjects of this study.They were divided into control group(n=45)and observation group(n=45)by random number table method.The control group was treated with conventional drugs,and the observation group was given intravenous infusion of Edaravone and Dexborneol on the basis of the control group.Two groups were treated for 4 weeks.The cognitive functions[mini-mental state examination(MMSE)and montreal cognitive assessment(MoCA)scores],degree of clinical dementia[clinical dementia rating(CDR)scores],daily living abilities[modified Barthel index(MBI)]and superoxide dismutase(SOD)levels,malondialdehyde(MDA),interferon-γ(IFN-γ),homocysteine(Hcy)levels were compared between two groups before and after treatment,the clinical efficacy of the two groups was evaluated.Result:Compared with before treatment,the CDR scores,MDA levels,Hcy levels and IFN-γlevels of both groups were decreased after treatment,and those in the observation group were lower than those of the control group,with statistical significance(P<0.05).Compared with before treatment,MMSE scores,MoCA scores,MBI,SOD levels of both groups were increased after treatment,and those in observation group were higher than those of control group,the differences were statistically significant(P<0.05).The total clinical effective rate of the observation group was 93.33%,which was higher than 77.78%of the control group,the difference was statistically significant(P<0.05).Conclusion:Edaravone and Dexborneol treatment can effectively improve cognitive functions and behavioral abilities in elderly patients with vascular dementia,reduce oxidative stress,and enhance the overall treatment efficacy rate.